Compare Medpace Holdings Inc (MEDP) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Northrop Grumman Corporation — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Northrop Grumman Corporation trades at $508 (market cap $74.42B). The key difference: Northrop Grumman Corporation is far larger — about 4.9× Medpace Holdings Inc's market cap, and Northrop Grumman Corporation pays a 1.79% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | NOC | |
|---|---|---|
Market Cap | $15.08B | $74.42B |
Sector | Technology | Industrials |
52-Week High | $620.59 | $768.02 |
52-Week Low | $308.88 | $496.02 |
Enterprise Value | $14.55B | $88.65B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Northrop Grumman (NOC) trades at $524.14, up 0.49% with a bearish technical signal despite strong fundamentals. The company shows consistent earnings beats, with Q1 2026 EPS of $6.14 exceeding expectations of $6.06. Recent news highlights defense budget optimism and a $312.3M Navy contract for electronic warfare systems. Technical indicators show RSI at oversold levels near support at $518, while moving averages signal bearish momentum.
The investment outlook remains positive with analyst consensus at Buy (57% of 35 analysts) and a $655 price target representing 25% upside. Risks include execution challenges in defense programs and potential margin pressure. Strong cash flow generation and a $96B backlog support long-term growth, though near-term technical weakness may present entry opportunities for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
